Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
Koutsilieris
Michael
M
Department of Experimental Physiology, Medical School, National & Kapodistrian University of Athens, Goudi-Athens, Greece. mkouts@medscape.com
Dimopoulos
Theodore
T
Milathianakis
Constantine
C
Bogdanos
John
J
Karamanolakis
Dimitrios
D
Pissimissis
Nicholas
N
Halapas
Antonis
A
Lembessis
Peter
P
Papaioannou
Andreas
A
Sourla
Antigone
A
D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D003907:Dexamethasone / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013004:Somatostatin / Q000031:analogs & derivatives*
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D013004:Somatostatin; D003907:Dexamethasone